Information  X 
Enter a valid email address

Benchmark Hlgs PLC (BMK)

  Print   

Tuesday 28 June, 2016

Benchmark Hlgs PLC

Half-year Report

RNS Number : 4167C
Benchmark Holdings PLC
28 June 2016
 

 

28 June 2016

BENCHMARK HOLDINGS PLC

("Benchmark" or the "Company" or the "Group")

 

INTERIM RESULTS 2016

 

INVE ACQUISITION COMPLETES GLOBAL PLATFORM

 

Benchmark, the international biotechnology and food chain sustainability business announces its Interim Results for the six months ended 31 March 2016 (the "period").

Financial Highlights:

·     Revenue increased by 142% to £48.0m (H1 2015: £19.8m). Like for like sales, excluding businesses acquired in either 2016 or 2015, increased 42% to £13.3m (H1 2015: £9.4m).

·     EBITDA from Trading Activities1 grew by £8.3m to £9.5m (H1 2015: £1.2m)

·     Acquisition of INVE Aquaculture in December 2015 for $342m (c.£230m) created new Advanced Animal Nutrition division

Funded via successful £219m (gross) equity raise

$70 million revolving credit facility secured to support the equity raise and the enlarged group's working capital needs

·     Temporary closure of Chilean border to Icelandic produced salmon eggs impacted Breeding and Genetics revenues

·     Operating loss of £15.2m (H1 2015: £4.0m) after increase of investing activities to £18.8m (H1 2015: £3.6m), including £11.8m of expensed acquisition and integration costs

·     Expensed R&D increased by 150% to £6.0m (H1 2015: £2.4m)

·     £8.3m invested in new vaccine manufacturing capacity at Braintree and marine R&D facilities at Ardtoe

Operational highlights:

·     Progress made on key strategic investment objectives:

Transformative acquisition of INVE Aquaculture in December 2015, more than doubled the size of the Group's operations

Continued investment in scientific research and development resources, and encouraging progress in the development pipeline

·     INVE integration progressing well with first operational synergies realised

·     Braintree manufacturing facility expected to enter commissioning by September 2016

·     First sales of new products in Animal Health and Breeding & Genetics

·     Recovery of market share for Salmosan®/Byelice® in Chile with some discounting of selling price

·     Challenging first half for Breeding & Genetics due to temporary border closure and the impact of El Niño on climatic conditions

·     Product pipeline of 85 products, with a potential addressable market of £742m per annum

·     Good progress with HypoCat product development

Alex Hambro, Chairman of Benchmark, said: "The integration of INVE Aquaculture into the Benchmark Group has transformed the business and largely completes our divisional structure. The benefit of securing diversified revenue streams is becoming increasingly apparent and we expect further revenue streams to materialise during the remainder of this calendar year as our product development pipeline matures and benefits are reaped from the capital expended upgrading Braintree's vaccine production facility and Ardtoe's aquaculture trials facilities."

 

For further information, please contact:

Benchmark Holdings plc     Tel: 020 7920 3150

Malcolm Pye, CEO

Roland Bonney, COO  

Rachel Aninakwah, Communications 

 

Numis Securities Tel: 020 7260 1000

Michael Meade / Freddie Barnfield (Corporate Finance)

James Black (Corporate Broking)

 

Tavistock    Tel: 020 7920 3150

Matt Ridsdale / Niall Walsh     

 

Notes to Editors:

Founded in 2000, Benchmark represents a new model in sustainable business development. Over the last decade it has built a successful group of companies on the economics of a sustainable food chain. The Group is growing in response to a rapidly increasing demand for sustainable food chains, and in particular for seafood, from both mature and emerging markets.

 

Benchmark is an ethical group with an explicit policy based on the "3E's" definition of a sustainable business - ethics, environment and economics - which guides its strategy and operations.  The Group has five divisions: Advanced Animal Nutrition which provides cutting edge nutritional products and services to the aquaculture industry and is a world leader in the feeding of the larval stages of shrimp and marine fish production, Breeding and Genetics which comprises a world-leading Salmon and aquaculture breeding business, Animal Health which researches, manufactures and markets medicines and vaccines particularly for aquaculture, Sustainable Science which researches and informs sustainable development in the food industry, and Technical Publishing which effects technology transfer through online publishing and education. Benchmark operates internationally with offices in England, Scotland, Belgium, Ireland, Norway, Iceland, USA, Brazil, China, Moscow, India, Thailand and Chile.  As at 1 May 2016, Benchmark employs 881 people.

 

For further information on Benchmark please visit www.benchmarkplc.com

 

1.   EBITDA from Trading Activities excludes costs relating to Investing Activities from reported IFRS numbers. Investing Activities comprise exceptional restructuring costs of £0.3m (H1 2015: £0.0m), acquisition costs of £11.8m (H1 2015: £0.1m net credit), pre-operational expenses for new ventures of £0.5m (H1 2015: £1.1m) and research and development expenditure of £6.0m (H1 2015: £2.4m).

  

 

Benchmark Holdings plc
 
Chairman’s Statement

CHAIRMAN'S STATEMENT

 

I am pleased to report the Group's Interim Results for the period to 31 March 2016.

 

We have made significant progress in a busy first half of the 2016 financial year as we continue to develop and diversify Benchmark into a group which comprehensively serves the needs of our customers whilst also providing us with multiple revenue streams by sector, technology and geography.

 

As noted in the 2015 annual report, we completed the transformative acquisition of INVE Aquaculture Holdings BV ("INVE") in December 2015 which more than doubled the scale of the group's operations.  INVE now forms the Advanced Animal Nutrition division. The consideration for the acquisition was $342m (c.£230m) which was funded through a combination of an equity raise and drawdown of a new debt facility.

 

The integration of INVE is progressing well, with a solid performance from the new division in the first half and the first operational synergies with the rest of the Benchmark Group now being realised.  I am pleased to see the quality of our divisional management teams come to the fore as the synergies available to the enlarged group are exploited.

 

Our strategy of diversification is showing its importance, with the strong performance of the Advanced Animal Nutrition division and the improved performance of the Animal Health division compared to H1 2015, compensating for the impact of the well-documented issues faced by the Breeding and Genetics division arising from the temporary closure of the Chilean border to Icelandic salmon eggs.  The Chilean border finally reopened to imports of salmon eggs from Iceland in early March, but the four month closure caused the division's sales to fall behind our expectations.  This sales shortfall was compounded by environmental factors in Chile linked to El Niño, however, taking into account the results of the other divisions, the Group remained on track overall.

 

Our pipeline of new technologies and products remains a focus, and first sales of a new aquaculture vaccine for sea bass were made in June 2016.  The product, which is targeted at the Mediterranean market, has been developed, is manufactured and will be distributed entirely by the Group, with customer liaison being managed by the INVE team; an example of the operational synergies mentioned above.  Furthermore, the investment in the new vaccine manufacturing facilities at Braintree and aquaculture trials facilities at Ardtoe are coming online in the next few months, providing the vital infrastructure required to deliver the Group's development portfolio.

 

Results

 

Revenue for the period increased by 142% to £48.0m (H1 2015: £19.8m; FY 2015: £44.2m), with the bulk of the growth (£20.6m) arising from three months of trading from the INVE acquisition.  The acquisitions completed in the financial year 2015 (the companies acquired to create the Breeding and Genetics division and Improve International held within the Technical Publishing division) have also contributed for a full six months in H1 2016.  As a result of the difficult trading conditions faced by the Breeding and Genetics division, revenues in the six month period were £10.7m compared to £9.8m for three months in H1 2015. 

 

Excluding acquisitions, underlying sales increased by 42% mainly due to the improved performance in the Animal Health division.  The introduction of new volume supply agreements and rewards for customer loyalty in response to the increased competition for Byelice (Salmosan) have shown improvement in revenues in both Chile and Norway.

 

Operating costs relating to Trading Activities (excluding amortisation and depreciation) in the first half doubled from the comparative period to £11.5m (H1 2015: £5.7m; FY 2015: £13.7m), with £3.4m of the increase coming from the newly created Advanced Animal Nutrition division.  The remainder of the increase reflects the inclusion of financial year 2015 acquisitions for a full period and increased activity within the Animal Health division.  Following the INVE acquisition, group headcount at the half year was 855 (30 September 2015: 402).

 

The Group continues to separate the statutory IFRS results into Trading Activities and Investing Activities, in line with many of its peers in the sector, to present better the underlying performance and development of the business.  This is how the board monitors progress of the existing group businesses.  Trading Activities are those related to products and services that have been developed and are producing revenue streams, while Investing Activities relate to the costs associated with acquiring new businesses and products and services being developed for future revenue streams and include a pipeline of vaccines at various stages of the development cycle.

 

EBITDA from Trading Activities in the first six months was £9.5m, an increase of £8.3m compared to H1 2015, with the bulk of the growth again arising from the post-acquisition profits of the Advanced Animal Nutrition division of £7.1m.  The Animal Health division saw an increase in Trading EBITDA to £2.0m (H1 2015: £0.5m loss; FY 2015: £2.1m profit) as sales have recovered against the low volumes in the comparative period. 

 

Earnings per share from Trading Activities of 0.94p is up on last year by 1.47p (H1 2015: loss per share from Trading Activities 0.53p; FY 2015 loss per share 1.13p).

 

The Group's statutory IFRS earnings (including both Trading and Investing Activities), set out in the Consolidated Income Statement, show an EBITDA loss for the first half of £9.1m (H1 2015: loss of £2.2m; FY 2015: loss £7.2m).  Basic and diluted earnings per share are both losses of 3.09p per share (H1 2015: basic and diluted loss per share of 2.49p; FY 2015: basic and diluted loss per share of 5.96p).

 

EBITDA from Trading Activities excludes from reported IFRS numbers those costs that relate to Investing Activities.  Costs relating to Investing Activities (excluding depreciation and amortisation) have increased by £15.2m to £18.6m in the period (H1 2015: £3.4m; FY 2015: £9.7m).  Investment costs in the period comprise acquisition and integration costs of £11.8m (H1 2015: net credit of £0.1m; FY 2015: costs of £1.3m), exceptional restructuring costs of £0.3m (H1 2015: £nil; FY 2015: £0.2m), pre-operational expenses for new ventures of £0.5m (H1 2015: £1.1m; FY 2015: £1.6m) and research and development expenditure of £6.0m (H1 2015: £2.4m; FY 2015: £6.6m).  As well as the increase relating to the continued focus on R&D activity in progressing the Group's pipeline of innovative products and technologies, which has expanded following recent acquisitions, the main impact is from the costs incurred on the transformative acquisition of INVE in December 2015.  Total net costs of £12.4m were incurred on the acquisition, £4.4m of which related to the raising of new equity to fund the acquisition and which was therefore offset against share premium account.  The remaining £8.0m of acquisition and integration costs included within the income statement is after a gain of £3.7m made on a foreign currency instrument entered into to fix the exchange rate for the US dollar consideration paid on the acquisition which is included in finance income.  Acquisition and integration costs in H1 2015 were a net credit due to similar foreign currency differences on the acquisitions of SalmoBreed and StofnFiskur producing a gain of £1.9m.

 

After all of the above, the Group made an operating loss of £15.2m in the period (H1 2015: £4.0m loss; FY 2015: £11.6m loss).

 

On 30 December 2015 the Company raised gross proceeds of £186m through the placing of 215,922,141 new ordinary shares, the proceeds of which together with a further 38,635,671 new ordinary shares issued on 31 December 2015 formed part of the consideration for the acquisition of INVE.

 

Strategy and markets

 

Benchmark now has five divisions operating in four growing global markets which are the fundamental building blocks of a sustainable food chain. 

 

·     Aquaculture is the fastest growing livestock sector with CAGR of 5.1%, and at $119bn is now a larger market than beef (source: FAO).  The breeding and genetics market within aquaculture is estimated to be $1.5bn, and the market for specialist nutritional products for marine fish, shrimp and tilapia $2.0bn.

·     The animal health market, including diagnostic, medicated feed and veterinary services is estimated at between $92bn-$102bn, with the animal medicines and vaccines sector estimated at around $22bn.  This is currently projected to grow at a CAGR of 5.7% per annum (source: Vetnosis).

·     Sustainability consulting is a $13.8bn market growing at between 4%-5% per annum.  The market is categorised as strategic consulting services ($1.2bn) and technical sustainability consulting ($12.6bn) (source: Verdantix)

·     The Science technical and medical publishing market, a $26bn global market is projected to grow at a CAGR of 4.2% (source: Outsell).

 

We have now completed the process of creating a scalable Group structure which serves customers and shareholders through its five operating divisions.  The businesses acquired last financial year are well integrated, and the integration of INVE is progressing to plan.  This acquisition has further solidified the Group's diversification of its income streams, has expanded the product pipeline and opened up new potential synergies within the enlarged group.  Management is focussed on exploiting these synergies to maximise growth within all of its divisions.

 

Operations

 

Animal Health Division

 

The Animal Health division has seen significant improvement in year on year sales of Salmosan / Byelice with total revenue and contribution ahead of the first half of last year.  EBITDA from Trading Activities for the division was a profit of £2.0m (H1 2015: loss of £0.5m; FY 2015: profit of £2.1m). 

 

The extension of the division's vaccine manufacturing capacity at its Braintree site is almost complete, with the new Braintree Biotech Building expected to enter commissioning by September 2016.  Benchmark Vaccines Ltd has successfully won a new companion animal vaccine toll manufacturing contract with a global animal health company.

 

The division's product development pipeline continues to progress and is one of the strongest in the aquaculture arena, comprising 56 products covering a total addressable market of approximately £578m per annum.  Work on the pipeline products and technologies is accelerating as we continue to integrate the necessary expertise and resources to exploit the pipeline's full potential.  R&D costs (including amortisation of acquired R&D assets) of £4.5m, all of which have been expensed as the criteria for capitalising development costs had not been met, have been invested in the product pipeline in the period (H1 2015: £2.3m).  The development of a new sea lice treatment continues to plan and sales of trial batches have commenced of the first of our new aquaculture vaccines.  This vaccine will target marine fish production in the Mediterranean and the INVE sales team is assisting with customer introductions.  There is good progress with the HypoCat product development.

 

Breeding and Genetics Division

 

In line with guidance provided at year end, the Breeding and Genetics division experienced a difficult first half as a result of the closure of the Chilean border to Icelandic salmon eggs.  Recovery was slower than anticipated, aggravated by lower stocking in the Chilean industry in response to environmental challenges, with sales significantly impacted.  Despite the inclusion of a full six months' results in H1 2016 for the businesses acquired in December 2014 and July 2015, EBITDA from Trading Activities fell by £1.3m to £1.8m (H1 2015: £3.1m; FY 2015 £4.6m). 

 

In order to ensure active management of future threats related to biosecurity and satisfy anticipated growth in demand for its products the division is close to completing a study into the feasibility of building a land based production facility in Norway. 

 

The division has made good progress with the launch of new products in the period. Of particular note was the announcement of a major breakthrough in genetic breeding programmes for Pancreas Disease (PD) and sea lice resistance through Genomic Selection. Whilst this method is already recognized in genetic science for other species, and can provide a more accurate and safer selection than by using traditional methods, Genomic Selection has never been used in aquaculture before. Benchmark believes that the use of this method can provide a significant advancement in developing resistance to both PD and sea lice in salmon, and thus provide significant savings for the industry.  The division's pipeline of products now includes 10 products with an addressable market of £45m.

 

Advanced Animal Nutrition Division

 

The division was formed, following the acquisition of INVE, mid-way through the period and has performed well, with EBITDA from Trading Activities at £7.1m.  The management team is working closely with the Benchmark Operations Board and the integration is proceeding to plan with the first phase of operational synergies being realised.  A new group wide key account management programme has been initiated and opportunities to utilise INVE's market leading distribution network are being developed.  The Benchmark and INVE R&D teams are coordinating their work on product development in order to maximise opportunities for combined nutrition and health products.  Customer response to the acquisition has been extremely positive, with their support being demonstrated by the number of new enquiries about the Group's offering of genetics, nutrition and animal health products rising sharply from new customers and new product sectors.  Work is also underway to incorporate Benchmark's primary stage algal feed business, TomAlgae, into the INVE sales, marketing and R&D structure.  Good progress has been made with INVE's pipeline of new products with 6 achieving first sales in the period.

 

The division's pipeline now includes 19 products with an addressable market of £119m.

 

Sustainability Science Division

 

The Sustainability Science division continues to provide consultancy and R&D services through its expertise across all parts of the food chain and its working research farms and sites, helping our partners grow and source food more efficiently and ethically.  Significant investment has been completed in the period at Ardtoe, Scotland and the new aquaculture trials facilities are coming online to provide the vital infrastructure to deliver the Group's development portfolio.

 

The division completed its reorganisation in the period and has realigned its cost base with the services it provides.  As a result, EBITDA from Trading Activities improved by £0.2m to a small loss of £0.1m (H1 2015: loss £0.3m; FY 2015: loss £0.5m).

 

Technical Publishing Division

 

The Technical Publishing Division, which provides access to expertise, education and knowledge transfer for people and businesses in the agriculture, aquaculture, veterinary and global food supply chain industries, has shown improved performance in the period compared to prior year.  Improve International (acquired in February 2015) is now fully integrated and continuing to develop its position as Europe's number one provider of continuing professional development to vets.  EBITDA from Trading Activities for the half year rose to £0.3m (H1 2015: £0.1m; FY 2015: £0.3m).  The Aquaculture UK business (acquired in June 2015) held its flagship industry technical conference in May 2016 with record attendances.

 

Funding

 

On 30 December 2015, the Group secured a revolving credit facility with a 5 year term of up to $70m in order to provide part of the funding required for the acquisition of INVE and to support working capital for the enlarged group. The facility is secured on certain of the Group's assets and attracts interest at a variable rate based on LIBOR plus a margin which is dictated by the performance of the Group.  As at 31 March 2016 $55m of the revolving credit facility had been drawn down.  The balance of the facility remains available to fund working capital and small scale capital projects, with leverage and interest cover covenants to be tested on a quarterly basis.

 

Cashflow and Net Cash

 

Net cashflow from operations was an outflow of £8.9m (H1 2015: outflow £5.2m; FY 2015 outflow £9.0m) due to the loss in the period, which includes the significant investing activities outlined above, and increased working capital demands of the enlarged group.  Cashflows were dominated by the proceeds of the share placing in December 2015, in which gross proceeds of £186m (£181m net of costs) were raised.  All of the proceeds raised were used to fund the acquisition of INVE in the period, together with some of the receipts from the new debt facility entered into in December 2015.  The balance of the purchase price was settled by the issue of new shares.

 

Capex in the period totalled £11.2m as investment nears completion on the new manufacturing plant at Braintree and the marine research facilities at Ardtoe, Scotland (H1 2015; £2.7m; FY 2015: £14.0m).

 

Cash at period end stood at £23.0m and borrowings drawn under the rolling credit facility, net of debt raising costs, stood at £37.6m giving the group a net debt position of £14.6m.

 

Taxation

 

There was a tax credit in the period of £1.3m (H1 2015: charge £0.5m; FY 2015: charge £0.4m).  There were overseas tax charges in the Breeding and Genetics division of £0.3m and in the Advanced Animal Nutrition division of £0.6m, offset by deferred tax credits on the reversal of temporary differences, mainly on intangible assets arising on consolidation from recent acquisitions.  No deferred tax assets have been provided on the losses made in the period.

 

Dividend

 

No dividends have been paid or proposed in the six months to 31 March 2016.  The Board will review the Group's position again at the full year end.

 

Outlook

 

The group remains on track for the full year despite the fact that El Niño has had an impact on the climate in South East Asia and Latin America and the algal bloom in Chile has reduced total salmon biomass across the Chilean industry.  Such climatic changes always have the potential to significantly influence sales of aquaculture health products, salmon eggs or advanced nutrition, and the board continues to monitor the situation.

 

The long term drivers of growth in the group's sectors are clearly positive. The recent expansion through targeted acquisition now allows Benchmark to leverage synergies by offering an integrated package of products and services to its customers, and key account management is being introduced to strengthen the group's ability to exploit the significant opportunities in the markets it serves.

 

As a result of the considered investment made in our product pipeline in recent years, we have a portfolio of technology of considerable value.  The product pipeline, combined with our world class research and manufacturing facilities, underpins our future growth potential and are sources of considerable confidence for the board.

 

The board is currently assessing the impact of the result of the UK's EU membership referendum.  Whilst the decision to leave the EU will affect UK trade agreements and relevant European business related legislation, there are more short term factors affecting companies like Benchmark.  While the group operates in many territories, most of its operations and sales do not involve EU countries, so the impact on trading of the result of the referendum will largely be mitigated.  The most immediate impact relevant to Benchmark is that on the UK currency.  With a large proportion of the group's sales transacted in US dollars, volatile GBP exchange rates may lead to increased exchange gains or losses, albeit these will be hedged by raw materials sourced in US dollars and by Benchmark's US dollar denominated borrowing facility.

 

I would like to thank our shareholders for their continued support and look forward to updating you again on the full year results.

 

 

 

 

The Hon. Alexander Hambro

Chairman

 

28 June 2016

 

 

 

 

Benchmark Holdings plc
 
Independent Review Report to Benchmark Holdings plc
Introduction 

We have been engaged by the company to review the condensed set of financial statements in the half-yearly report for the six months ended 31 March 2016 which comprises the consolidated income statement, the consolidated statement of comprehensive income, the consolidated balance sheet, the consolidated statement of changes in equity, the consolidated cash flow statement and the related explanatory notes.  We have read the other information contained in the half-yearly report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements. 

This report is made solely to the company in accordance with the terms of our engagement.  Our review has been undertaken so that we might state to the company those matters we are required to state to it in this report and for no other purpose.  To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company for our review work, for this report, or for the conclusions we have reached. 
Directors' responsibilities 

The half-yearly report is the responsibility of, and has been approved by, the directors.  The directors are responsible for preparing the half-yearly report in accordance with the AIM Rules. 

The annual financial statements of the group are prepared in accordance with IFRSs as adopted by the EU.  The condensed set of financial statements included in this half-yearly report has been prepared in accordance with the recognition and measurement requirements of IFRSs as adopted by the EU. 

Our responsibility 

Our responsibility is to express to the company a conclusion on the condensed set of financial statements in the half-yearly report based on our review. 

Scope of review 

We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Auditing Practices Board for use in the UK.  A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.  A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK and Ireland) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit.  Accordingly, we do not express an audit opinion. 

Conclusion 

Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly report for the six months ended 31 March 2016 is not prepared, in all material respects, in accordance with the recognition and measurement requirements of IFRSs as adopted by the EU and the AIM Rules. 

 

 

Ian Beaumont

for and on behalf of KPMG LLP 

Chartered Accountants 

1 Sovereign Square, Sovereign Street, Leeds, LS1 4DA

28 June 2016

 

Benchmark Holdings plc
 
Consolidated Income Statement
for the 6 months ended 31 March 2016

 

 

6 months ended 31 March 2016

6 months ended 31 March 2015

12 months ended 30 September 2015

 

 

Trading Activities

Investing Activities

Total

Trading Activities

Investing Activities

Total

Trading Activities

Investing Activities

Total

 

Notes

 (unaudited)

(unaudited)

(unaudited)

(unaudited)

(unaudited)

(unaudited)

(audited)

(audited)

(audited)

 

 

£000

£000

£000

£000

£000

£000

£000

£000

£000

 

Revenue

 

47,965

-

47,965

19,779

-

19,779

44,199

-

44,199

Cost of sales

 

(27,012)

-

(27,012)

(12,870)

-

(12,870)

(28,102)

-

(28,102)

Gross profit

 

20,953

-

20,953

6,909

-

6,909

16,097

-

          16,097

Operating costs

 

(11,489)

(18,265)

(29,754)

(5,722)

(3,388)

(9,110)

(13,674)

(9,494)

(23,168)

Operating costs - Exceptional

8

-

(294)

(294)

-

(20)

(20)

-

(160)

(160)

 

EBITDA

 

9,464

(18,559)

(9,095)

1,187

(3,408)

(2,221)

2,423

(9,654)

(7,231)

Depreciation

11

(980)

(84)

(1,064)

(640)

-

(640)

(1,113)

(191)

(1,304)

Amortisation

12

(4,870)

(123)

(4,993)

(917)

(184)

(1,101)

(2,825)

(239)

(3,064)

Operating profit / (loss)

 

3,614

(18,766)

(15,152)

(370)

(3,592)

(3,962)

(1,515)

(10,084)

(11,599)

Finance cost

 

(1,254)

(1)

(1,255)

-

-

-

(34)

-

(34)

Finance income

 

47

3,743

3,790

125

-

125

260

14

274

 

 

 

 

 

 

 

 

 

 

 

Profit/(loss) on ordinary activities before taxation

 

2,407

(15,024)

(12,617)

(245)

(3,592)

(3,837)

(1,289)

(10,070)

(11,359)

Tax on profit/(loss) on ordinary activities

9

1,032

230

1,262

(518)

-

(518)

(751)

355

(396)

Profit/(loss) for the period

 

3,439

(14,794)

(11,355)

(763)

(3,592)

(4,355)

(2,040)

(9,715)

(11,755)

 

 

 

 

 

 

 

 

 

 

 

Profit/(loss) for the period attributable to:

 

 

 

 

 

 

 

 

 

 

-       Owners of the parent

 

3,448

(14,794)

(11,346)

(964)

(3,592)

(4,556)

(2,273)

(9,715)

(11,988)

-       Non-controlling interest

 

(9)

-

(9)

201

-

201

233

-

233

 

 

3,439

(14,794)

(11,355)

(763)

(3,592)

(4,355)

(2,040)

(9,715)

(11,755)

 

 

 

 

 

 

 

 

 

 

 

Basic earnings / (loss) per share (pence)

10

0.94

 

(3.09)

(0.53)

 

(2.49)

(1.13)

 

(5.96)

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings / (loss) per share (pence)

10

0.94

 

(3.09)

(0.53)

 

(2.49)

(1.13)

 

(5.96)

 

Benchmark Holdings plc
 
Consolidated Statement of Comprehensive Income
for the 6 months ended 31 March 2016

 

6 months ended 31 March 2016

 

6 months ended 31 March 2015

 

12 months ended 30 September 2015

 

Trading Activities

Investing Activities

Total

 

Trading Activities

Investing Activities

Total

 

Trading Activities

Investing Activities

Total

 

(unaudited)

(unaudited)

(unaudited)

 

(unaudited)

(unaudited)

(unaudited)

 

(audited)

(audited)

(audited)

 

£000

£000

£000

 

£000

£000

£000

 

£000

£000

£000

 

 

 

 

 

 

 

 

 

 

 

 

Profit/(loss) for the period

3,439

(14,794)

(11,355)

 

(763)

(3,592)

(4,355)

 

(2,040)

(9,715)

(11,755)

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive income/(expense)

 

 

 

 

 

 

 

 

 

 

 

Movement on foreign exchange reserve

13,146

-

13,146

 

(1,071)

-

(1,071)

 

(2,812)

-

(2,812)

 

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income/(expense) for the period

16,585

(14,794)

1,791

 

(1,834)

(3,592)

(5,426)

 

(4,852)

(9,715)

(14,567)

 

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income/(expense) for the period attributable to:

 

 

 

 

 

 

 

 

 

 

 

-       Owners of the parent

16,487

(14,794)

1,693

 

(2,053)

(3,592)

(5,645)

 

(5,071)

(9,715)

(14,786)

-       Non-controlling interest

98

-

98

 

219

-

219

 

219

-

219

 

 

 

 

 

 

 

 

 

 

 

 

 

16,585

(14,794)

1,791

 

(1,834)

(3,592)

(5,426)

 

(4,852)

(9,715)

(14,567)

 

 

 

 

Benchmark Holdings plc
 
Consolidated Balance Sheet
as at 31 March 2016

 

 

As at 31
March 2016

As at 31
March 2015

As at 30
September 2015

 

Notes

(unaudited)

(unaudited)

(audited)

 

 

£000

£000

£000

Assets

 

 

 

 

Non-current assets

 

 

 

 

Property, plant and equipment

11

41,224

14,891

25,141

Intangible assets

12

323,662

59,210

65,872

Investments

 

520

95

147

Trade and other receivables

 

156

450

293

Biological and agricultural assets

 

3,411

1,954

3,392

Total non-current assets

 

368,973

76,600

94,845

 

 

 

 

 

Current assets

 

 

 

 

Inventories

 

21,772

5,666

5,359

Biological and agricultural assets

 

6,389

6,801

4,948

Trade and other receivables

 

35,034

10,493

15,353

Cash and cash equivalents

 

23,048

38,615

13,564

Total current assets

 

86,243

61,575

39,224

 

 

 

 

 

Total assets

 

455,216

138,175

134,069

 

 

 

 

 

Liabilities

 

 

 

 

Current liabilities

 

 

 

 

Trade and other payables

 

(36,670)

(10,140)

(24,368)

Loans and borrowings

 

(57)

(163)

(63)

Corporation tax liability

 

(2,379)

(428)

(860)

Provisions

 

(1,908)

(1,307)

(1,033)

Total current liabilities

 

(41,014)

(12,038)

(26,324)

 

 

 

 

 

Non-current liabilities

 

 

 

 

Loans and borrowings

13

(37,559)

(93)

(93)

Other payables

 

(9,151)

(16,265)

(7,330)

Deferred tax

 

(59,185)

(7,815)

(8,224)

Total non-current liabilities

 

(105,895)

(24,173)

(15,647)

 

 

 

 

 

Total liabilities

 

(146,909)

(36,211)

(41,971)

 

 

 

 

 

Net assets

 

308,307

101,964

92,098

 

 

 

 

 

Issued capital and reserves attributable to owners of the parent

 

 

 

 

Share capital

 

474

219

219

Share premium reserve

 

308,947

94,735

94,672

Capital redemption reserve

 

5

5

5

Retained earnings

 

(12,479)

6,240

(1,021)

Foreign exchange reserve

 

10,315

(1,015)

(2,724)

Equity attributable to owners of the parent

 

307,262

100,184

91,151

Non-controlling interest

 

1,045

1,780

947

 

 

 

 

 

Total equity and reserves

 

308,307

101,964

92,098

The notes on pages 15 to 26 are an integral part of this interim consolidated financial information.

 

Benchmark Holdings plc
 
Consolidated Statement of Changes in Equity
for the 6 months ended 31 March 2016

 

Share
capital

Other
reserves

Retained
  earnings

Total attributable
 to equity holders of
parent

Non-
controlling
interest

Total
equity

 

£000

£000

£000

£000

£000

£000

£000

 

 

 

 

 

 

 

 

As at 1 October 2014

 137

 26,903

 1,185

 9,017

 37,242

 10

 37,252

 

 

 

 

 

 

 

 

Comprehensive income for the period

 

 

 

 

 

 

 

(Loss)/profit for the period

-

-

 -

(4,556)

(4,556)

 201

(4,355)

Other comprehensive income

 -

 -

(1,089)

 -

(1,089)

 18

(1,071)

Total comprehensive income for the period

 -

 -

(1,089)

(4,556)

(5,645)

 219

(5,426)

 

 

 

 

 

 

 

 

Contributions by and distributions to owners

 

 

 

 

 

 

 

Equity acquisition

 -

 -

 -

 -

 -

 1,551

 1,551

Share based payment

 -

 -

 505

 -

 505

 -

 505

Deferred tax options on shares

 -

 -

 168

 -

 168

 -

 168

Combination of share based payment with retained earnings *

 -

 -

(1,779)

 1,779

 -

 -

 -

Share issue

 82

 69,918

 -

 -

 70,000

 -

 70,000

Share issue costs recognised through equity

 -

(2,086)

 -

 -

(2,086)

 -

(2,086)

Total contributions by and distributions to owners

 82

 67,832

(1,106)

 1,779

 68,587

 1,551

 70,138

 

 

 

 

 

 

 

 

As at 31 March 2015 (unaudited)

 219

 94,735

(1,010)

 6,240

 100,184

 1,780

101,964

 

 

 

 

 

 

 

 

Comprehensive income for the period

 

 

 

 

 

 

 

(Loss)/profit for the period

 -

 -

 -

(7,432)

(7,432)

 32

(7,400)

Other comprehensive income

 -

 -

(1,709)

 -

(1,709)

(32)

(1,741)

Total comprehensive income for the period

 -

 -

(1,709)

(7,432)

(9,141)

 -

(9,141)

 

 

 

 

 

 

 

 

Contributions by and distributions to owners

 

 

 

 

 

 

 

Share issue costs recognised through equity

 -

(63)

 -

 -

(63)

 -

(63)

Share based payment

 -

 -

 -

 243

 243

 -

 243

Deferred tax options on shares

 -

 -

 -

(72)

(72)

 -

(72)

Acquisition of non-controlling interest

 -

 -

 -

 -

 -

(833)

(833)

Total contributions by and distributions to owners

 -

(63)

 -

 171

 108

(833)

(725)

 

 

 

 

 

 

 

 

As at 30 September 2015 (audited)

 219

 94,672

(2,719)

(1,021)

 91,151

 947

 92,098

 

 

 

 

 

 

 

 

Comprehensive income for the period

 

 

 

 

 

 

 

Loss for the period

 -

 -

 -

(11,346)

(11,346)

(9)

(11,355)

Other comprehensive income

 -

 -

 13,039

 -

 13,039

 107

 13,146

Total comprehensive income for the period

 -

 -

 13,039

(11,346)

 1,693

 98

 1,791

 

 

 

 

 

 

 

 

Contributions by and distributions to owners

 

 

 

 

 

 

 

Share issue

 255

 218,665

 -

 -

 218,920

 -

   218,920

Share issue costs recognised through equity

 -

(4,390)

 -

 -

(4,390)

 -

(4,390)

Share based payment

 -

 -

 -

 304

 304

 -

 304

Deferred tax options on shares

 -

 -

 -

(416)

(416)

 -

(416)

 

 

 

 

 

 

 

 

Total contributions by and distributions to owners

 255

 214,275

 -

(112)

 214,418

 -

 214,418

 

 

 

 

 

 

 

 

As at 31 March 2016 (unaudited)

 474

 308,947

 10,320

(12,479)

 307,262

 1,045

 308,307

* To simplify presentation, the share based payment reserve was combined with the retained earnings reserve in the 6 months ended 31 March 2015.

 

Benchmark Holdings plc
 
Statement of Cash Flows for the 6 months ended 31 March 2016

 

 

6 months
ended 31
March 2016
(unaudited)

6 months
ended 31
March 2015
(unaudited)

12 months
ended 30
September 2015
(audited)

 

Notes

£000

£000

£000

 

 

 

 

 

Cash flows from operating activities

 

 

 

 

Loss before tax

 

(12,617)

(3,837)

(11,359)

Adjustments for:

 

 

 

 

Depreciation of property, plant and equipment

11

1,064

640

1,304

Amortisation of intangible fixed assets

12

4,993

1,101

3,064

Loss on sale of property, plant and equipment

 

114

-

21

Finance income

 

(60)

(125)

(274)

Finance expense

 

264

-

34

Foreign exchange gains

 

(3,275)

(1,709)

(1,445)

Share based payment expense

 

304

215

458

 

 

 

 

 

 

 

(9,213)

(3,715)

(8,197)

(Increase)/decrease in trade and other receivables

 

(13,257)

5,078

2,503

Decrease/(increase) in inventories and biological assets

 

312

(1,262)

(468)

Increase/(decrease) in trade and other payables

 

13,016

(5,307)

(2,645)

Increase/(decrease) in provisions

 

583

227

(47)

 

 

 

 

 

 

 

(8,559)

(4,979)

(8,854)

 

 

 

 

 

Income taxes paid

 

(309)

(177)

(105)

 

 

 

 

 

Net cash flows used in operating activities

 

(8,868)

(5,156)

(8,959)

 

 

 

 

 

Investing activities

 

 

 

 

Acquisition of subsidiaries, net of cash acquired

15

(191,176)

(37,775)

(47,568)

Purchase of investments

 

-

-

(52)

Purchases of property, plant and equipment

11

(11,192)

(2,668)

(14,038)

Purchase of intangibles

12

(9)

(83)

(182)

Proceeds from sale of fixed assets

 

-

-

148

Interest received

 

60

125

274

 

 

 

 

 

Net cash flows used in investing activities

 

(202,317)

(40,401)

(61,418)

 

 

 

 

 

Financing activities

 

 

 

 

Proceeds of share issue

 

185,693

70,000

70,000

Proceeds from bank borrowings (net of costs)

 

35,929

-

-

Share-issue costs recognised through equity

 

(4,390)

(2,086)

(2,149)

Net cash flow from derivative financial instruments

 

3,731

-

-

Repayment of bank borrowings

 

-

(238)

(332)

Interest paid

 

(198)

-

(34)

Payments to finance lease creditors

 

(96)

(15)

(55)

 

 

 

 

 

Net cash inflow from financing activities

 

220,669

67,661

67,430

 

 

 

 

 

Net increase/(decrease) in cash and cash equivalents

 

9,484

22,104

(2,947)

Cash and cash equivalents at beginning of period

 

13,564

16,511

16,511

 

 

 

 

 

Cash and cash equivalents at end of period

 

23,048

38,615

13,564

 

Benchmark Holdings plc
 
Unaudited notes to the interim statement for the 6 months ended 31 March 2016

1.     Financial information

 

This announcement does not constitute statutory financial statements within the meaning of the Companies Act 2006 and the interim financial information included within has not been audited.

 

This information has been approved for issue by the Board of Directors of Benchmark Holdings plc, a company domiciled and incorporated in the United Kingdom.

 

Statutory accounts for the year ended 30 September 2015 were approved by the Directors on 1 February 2016 and delivered to the Registrar of Companies. The audit report received on those accounts was unqualified and did not contain any emphasis of matter paragraph nor any statement under Section 498 of the Companies Act 2006.

 

2.     General information and basis of preparation

 

The financial information set out in these interim financial statements for the six months ended 31 March 2016 and the comparative figures for the six months ended 31 March 2015 are unaudited. They have been prepared in accordance with the recognition and measurement requirements of International Financial Reporting Standards (IFRS) and IFRIC interpretations issued by the International Accounting Standards Board (IASB) adopted by the European Union and the AIM Rules. They do not contain all the information required for statutory financial statements and should be read in conjunction with the consolidated financial statements of the Group for the year ended 30 September 2015, which have been prepared in accordance with IFRS as adopted by the European Union.

 

The interim financial statements comprise the financial statements of the Group and its subsidiaries at 31 March 2016. Subsidiaries are consolidated from the date of acquisition, being the date on which the Group obtained control, and continue to be consolidated until the date when such control ceases.

 

The interim financial statements incorporate the results of business combinations using the acquisition method. In the consolidated balance sheet, the acquiree's identifiable assets, liabilities and contingent liabilities are initially recognised at their fair values at the acquisition date.

 

Non-controlling interests, presented as part of equity, represent a proportion of a subsidiary's profit or loss and net assets that is not held by the Group. The total comprehensive income or loss of non-wholly owned subsidiaries is attributed to owners of the parent and to the non-controlling interests in proportion to their respective ownership interests.

 

On consolidation, the results of overseas operations are translated into sterling at rates approximating to those ruling when the transactions took place. All assets and liabilities of overseas operations, including goodwill arising on the acquisition of those operations, are translated at the rate ruling at the reporting date. Exchange differences arising are recognised in other comprehensive income and accumulated in the foreign exchange reserve.

 

Exchange differences recognised in the income statement in the Group entities' separate financial statements on the translation of long-term monetary items forming part of the Group's net investment in the overseas operation concerned are reclassified to other comprehensive income and accumulated in the foreign exchange reserve on consolidation.

 

The following adopted IFRSs have been issued but have not been applied by the Group in these financial statements. Their adoption is not expected to have a material effect on the financial statements.

·     IFRS 9: Financial Instruments (effective date 1 January 2018)

·     IFRS 15: Revenue from Contract with Customers (effective date 1 January 2017)

·     IFRS 16: Leases (effective date 1 January 2019)

·     Annual Improvements to IFRSs - 2012-2014 Cycle: (effective date 1 January 2016)

 

The adoption of other standards is not expected to have a material effect on the financial statements.

 

A financial review of the business is included in the Chairman's Statement.

 

 

 

3.     Share capital

 

On 30 December 2015, the Company issued 215,922,141 shares of 0.1p each at a price of 86p per share to fund the acquisition of INVE Aquaculture Holdings B.V. In addition, on 31 December 2015, the Company issued 38,635,671 shares of 0.1p each at 86p as part consideration for the acquisition. Non-recurring costs of £4.4 million were incurred in relation to the share placing and this has been charged to the share premium account.

 

On 2 March 2016, the Company issued a total of 50,742 shares of 0.1p each to 6 employees of the Group relating to share options granted in August 2013 and March 2015.

 

4.     Going concern

 

The Group's business activities, together with the factors likely to affect its future development, performance and position are set out in the Chairman's Statement.

 

The Directors have considered these factors, the likely performance of the business and possible alternative outcomes and the financing activities available to the Group.  Having taken all of these factors into consideration, including the impact on covenants relating to the external borrowing facility, the Directors confirm that forecasts and projections indicate that the Group and its Parent Company have adequate resources for the foreseeable future and at least for the period of 12 months from the date of signing the half year report. Accordingly, the financial information has been prepared on the going concern basis.

 

5.     Accounting policies

 

The accounting policies adopted are consistent with those of the financial year ended 30 September 2015.

 

Trading Activities and Investing Activities are disclosed and described separately in the interim financial information where it is necessary to do so to provide further understanding of the financial performance of the Group.

 

Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total earnings.

 

The Group acquired INVE Aquaculture Group during the period and the accounting policies for that group are consistent with those already applied for the existing group. The estimates of useful economic lives of intangible assets, as shown in note 12, have been updated to reflect the newly acquired assets.

 

6.     Estimates

 

The preparation of interim financial information requires management to make certain judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual amounts may differ from these estimates.

 

In preparing these interim financial statements the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements for the year ended 30 September 2015.

 

 

 

7.     Segment information

 

Operating segments are reported in a manner consistent with the reports made to the chief operating decision maker. It is considered that the role of chief operating decision maker is performed by the Board of Directors.

 

The Group operates globally and for management purposes is organised into reportable segments as follows:

 

·      Animal Health Division - provides veterinary services, environmental services diagnostics and animal health products to global aquaculture, and manufactures licenced veterinary vaccines and vaccine components;

·      Sustainability Science Division - provides sustainable food production consultancy, technical consultancy and assurance services;

·      Breeding and Genetics Division - harnesses industry leading salmon breeding technologies combined with state-of-the-art production facilities to provide a range of year-round high genetic merit ova;

·      Technical Publishing Division - promotes sustainable food production and ethics through online news and technical publications for the international agriculture and food processing sectors and through delivery of training courses to the industries;

·      Advanced Animal Nutrition -  manufactures and provides technically advanced nutrition and health products to the global aquaculture industry;

·      Corporate - the corporate segment represents revenues earned from recharging certain central costs to the operating divisions, together with unallocated central costs.

 

Measurement of operating segment profit or loss

As outlined in note 5, the Group separates its operations into Trading Activities and Investing Activities to report segmental performance. These measures are used by management for planning and reporting purposes. These measures are not defined in International Financial Reporting Standards and may not be comparable with similarly described measures used by other companies. Trading and Investing Activities are described further in note 14.

 

Inter-segment sales are priced along the same lines as sales to external customers, with an appropriate discount being applied to encourage use of Group resources at a rate acceptable to local tax authorities.  This policy was applied consistently throughout the current and prior period.

 

Six months ended 31 March 2016 (unaudited)

 

 

Animal Health

Sustainability Science

Breeding and Genetics

Technical Publishing

Advanced Animal Nutrition

Corporate

Inter-segment sales

Total

 

Notes

£000

£000

£000

£000

£000

£000

£000

£000

 

 

 

 

 

 

 

 

 

 

Revenue

 

12,204

1,502

10,669

4,201

20,611

1,272

(2,494)

47,965

Cost of sales

 

(7,778)

(1,130)

(7,090)

(2,466)

(10,149)

(482)

2,083

(27,012)

 

 

 

 

 

 

 

 

 

 

Gross profit / (loss)

 

4,426

372

3,579

1,735

10,462

790

(411)

20,953

Operating costs relating to Trading Activities

 

(2,413)

(432)

(1,746)

(1,469)

(3,355)

(2,294)

220

(11,489)

 

 

 

 

 

 

 

 

 

 

EBITDA from Trading Activities

 

2,013

(60)

1,833

266

7,107

(1,504)

(191)

9,464

 

 

 

 

 

 

 

 

 

 

Operating costs relating to Investing Activities:

 

 

 

 

 

 

 

 

 

R&D expenditure

14

(4,272)

-

(964)

-

(776)

-

13

(5,999)

Pre-operational expenses

14

(146)

(531)

-

-

-

-

172

(505)

Acquisition-related (expenses) / income

14

(107)

(8)

(1,108)

-

-

(10,538)

-

(11,761)

Exceptional items

8,14

-

(300)

-

-

-

-

6

(294)

 

 

 

 

 

 

 

 

 

 

EBITDA

 

(2,512)

(899)

(239)

266

6,331

(12,042)

-

(9,095)

Depreciation

 

(323)

(84)

(304)

(49)

(276)

(28)

-

(1,064)

Amortisation

 

(395)

-

(871)

(366)

(3,361)

-

-

(4,993)

Operating profit / (loss)

 

(3,230)

(983)

(1,414)

(149)

2,694

(8,340)

-

(15,152)

Finance cost

 

 

 

 

 

 

 

 

(1,255)

Finance income

 

 

 

 

 

 

 

 

3,790

Gross loss before tax

 

 

 

 

 

 

 

 

(12,617)

7.     Segment information (continued)

 

Six months ended 31 March 2015 (unaudited)

 

 

Animal Health

Sustainability Science

Breeding and Genetics

Technical Publishing

Advanced Animal Nutrition

Corporate

Inter-segment sales

Total

 

Notes

£000

£000

£000

£000

£000

£000

£000

£000

 

 

 

 

 

 

 

 

 

 

Revenue

 

7,819

1,649

9,843

2,059

-

1,653

(3,244)

19,779

Cost of sales

 

(6,465)

(1,213)

(5,100)

(1,531)

-

(638)

2,077

(12,870)

 

 

 

 

 

 

 

 

 

 

Gross profit / (loss)

 

1,354

436

4,743

528

-

1,015

(1,167)

6,909

Operating costs relating to Trading Activities

 

(1,843)

(740)

(1,599)

(472)

-

(2,235)

1,167

(5,722)

 

 

 

 

 

 

 

 

 

 

EBITDA from Trading Activities

 

(489)

(304)

3,144

56

-

(1,220)

-

1,187

 

 

 

 

 

 

 

 

 

 

Operating costs relating to Investing Activities:

 

 

 

 

 

 

 

 

 

R&D expenditure

14

(2,113)

-

(307)

-

-

-

-

(2,420)

Pre-operational expenses

14

(878)

(210)

-

-

-

-

-

(1,088)

Acquisition-related (expenses) / income

14

(84)

-

1,952

(16)

-

(1,732)

-

120

Exceptional items

8,14

-

-

-

-

-

(20)

-

(20)

 

 

 

 

 

 

 

 

 

 

EBITDA

 

(3,564)

(514)

4,789

40

-

(2,972)

-

(2,221)

Depreciation

 

(322)

(173)

(126)

(13)

-

(6)

-

(640)

Amortisation

 

(628)

-

(308)

(165)

-

-

-

(1,101)

Operating profit / (loss)

 

(4,514)

(687)

4,355

(138)

-

(2,978)

-

(3,962)

Finance cost

 

 

 

 

 

 

 

 

-

Finance income

 

 

 

 

 

 

 

 

125

Gross loss before tax

 

 

 

 

 

 

 

 

(3,837)

 

12 months ended 30 September 2015 (audited)

 

 

Animal Health

Sustainability Science

Breeding and Genetics

Technical Publishing

Advanced Animal Nutrition

Corporate

Inter-segment sales

Total

 

Notes

£000

£000

£000

£000

£000

£000

£000

£000

 

 

 

 

 

 

 

 

 

 

Revenue

 

21,098

3,134

15,871

6,967

-

2,271

(5,142)

44,199

Cost of sales

 

(14,524)

(2,229)

(9,912)

(4,677)

-

(1,463)

4,703

(28,102)

 

 

 

 

 

 

 

 

 

 

Gross profit / (loss)

 

6,574

905

5,959

2,290

-

808

(439)

16,097

Operating costs relating to Trading Activities

 

(4,445)

(1,399)

(1,339)

(2,006)

-

(4,924)

439

(13,674)

 

 

 

 

 

 

 

 

 

 

EBITDA from Trading Activities

 

2,129

(494)

4,620

284

-

(4,116)

-

2,423

 

 

 

 

 

 

 

 

 

 

Operating costs relating to Investing Activities:

 

 

 

 

 

 

 

 

 

R&D expenditure

14

(5,199)

-

(1,396)

-

-

-

-

(6,595)

Pre-operational expenses

14

(887)

(649)

-

-

-

(29)

-

(1,565)

Acquisition-related (expenses) / income

14

(65)

-

1,163

(18)

-

(2,414)

-

(1,334)

Exceptional items

8,14

-

509

(1)

-

-

(668)

-

(160)

 

 

 

 

 

 

 

 

 

 

EBITDA

 

(4,022)

(634)

4,386

266

-

(7,227)

-

(7,231)

Depreciation

 

(653)

(160)

(406)

(32)

-

(53)

-

(1,304)

Amortisation

 

(1,251)

(345)

(928)

(540)

-

-

-

(3,064)

Operating profit / (loss)

 

(5,926)

(1,139)

3,052

(306)

-

(7,280)

-

(11,599)

Finance cost

 

 

 

 

 

 

 

 

(34)

Finance income

 

 

 

 

 

 

 

 

274

Gross loss before tax

 

 

 

 

 

 

 

 

(11,359)

 

8.     Exceptional items

 

Items that are material because of their size or nature, non-recurring and whose significance is sufficient to warrant separate disclosure and identification within the consolidated financial statements are referred to as exceptional items. The separate reporting of exceptional items helps to provide an understanding of the Group's underlying performance.

 

 

 

6 months
ended 31
March 2016
(unaudited)

6 months
ended 31
March 2015
(unaudited)

12 months
ended 30
September 2015
(audited)

 

 

£000

£000

£000

 

 

 

 

 

Exceptional IPO costs

 

-

20

24

Exceptional restructuring costs

 

294

-

136

 

 

 

 

 

Total exceptional costs

 

294

20

160

 

Restructuring costs of £294,000 were incurred within the Sustainability Science Division during the period.

 

All exceptional items are included within operating costs on the face of the income statement.

 

 

9.     Taxation

 

 

 

6 months
ended 31
March 2016
(unaudited)

6 months
ended 31
March 2015
(unaudited)

12 months
ended 30
September 2015
(audited)

 

 

£000

£000

£000

Analysis of charge in period

 

 

 

 

 

 

 

 

 

Current tax:

 

 

 

 

Current income tax expense on profits for the period

 

872

692

877

Adjustment in respect of prior periods

 

(336)

-

(23)

Total current tax

 

536

692

854

 

 

 

 

 

Deferred tax expense

 

 

 

 

Origination and reversal of temporary differences

 

(1,798)

(174)

(284)

Deferred tax movements in respect of prior periods

 

-

-

(174)

Total deferred tax

 

(1,798)

(174)

(458)

 

 

 

 

 

Total tax (credit)/charge

 

(1,262)

518

396

 

The reasons for the difference between the actual tax charge for the period and the standard rate of corporation tax in the United Kingdom applied to the result for the period are as follows:

 

 

 

6 months
ended 31
March 2016
(unaudited)

6 months
ended 31
March 2015
(unaudited)

12 months
ended 30
September 2015
(audited)

 

 

£000

£000

£000

 

 

 

 

 

Accounting loss before income tax

 

(12,617)

(3,837)

(11,359)

 

 

 

 

 

 

 

 

 

 

Expected tax charge based on the standard rate of UK corporation tax at the domestic rate of 20% (31 March 2015: 20%, 2015: 20%)

 

(2,523)

(767)

(2,272)

Expenses not deductible for tax purposes

 

2,139

94

532

Research and development relief

 

(115)

(255)

(230)

Deferred tax not recognised

 

1,091

1,423

2,289

Adjustment to tax charge in respect of prior periods

 

(336)

-

(23)

Different tax rates in overseas jurisdictions

 

(1,518)

23

100

Total tax (credit)/charge

 

(1,262)

518

396

 

 

 

10.   Earnings per share

 

Basic earnings per share is calculated by dividing the profit attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares in issue during the period.

 

 

6 months
ended 31
March 2016
(unaudited)

6 months
ended 31
March 2015
(unaudited)

12 months
ended 30
September 2015
(audited)

 

 

 

 

 

Net loss attributable to equity holders of the parent (£000)

 

(11,346)

(4,556)

(11,988)

 

 

 

 

 

Weighted average number of shares in issue (thousands)

 

367,017

183,131

201,280

 

 

 

 

 

Basic loss per share from continuing operations (pence)

 

(3.09)

(2.49)

(5.96)

 

 

 

 

 

 

Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. This is done by calculating the number of shares that could have been acquired at fair value (determined as the average market price of the Company's shares for the period) based on the monetary value of the subscription rights attached to outstanding share options and warrants. The number of shares calculated above is compared with the number of shares that would have been issued assuming the exercise of the share options and warrants.

 

Therefore, the Company is required to adjust the earnings per share calculation in relation to the share options that are in issue under the Company's share based incentive schemes, and outstanding warrants, as follows:

 

 

6 months
ended 31
March 2016
(unaudited)

6 months
ended 31
March 2015
(unaudited)

12 months
ended 30
September 2015
(audited)

 

 

 

 

 

Net loss attributable to equity holders of the parent (£000)

 

(11,346)

(4,556)

(11,988)

 

 

 

 

 

Weighted average number of shares in issue (thousands)

 

367,017

183,131

201,280

 

 

 

 

 

Diluted loss per share from continuing operations (pence)

 

(3.09)

(2.49)

(5.96)

 

 

 

 

 

 

A total of 1,362,157 (H1 2015: 1,494,000; FY 2015: 2,401,186) potential ordinary shares have not been included within the calculation of statutory diluted earnings per share for the six months ended 31 March 2016 as they are antidilutive. However, these potential ordinary shares could dilute earnings per share in the future.

 

 

 

11.   Property, plant and equipment

 

 

Freehold Land and Buildings

Assets in the course of construction

Long Term Leasehold Property Improvements

Plant and Machinery

E commerce Infrastructure

Office Equipment and Fixtures

Total

 

£000

£000

£000

£000

£000

£000

£000

Cost or valuation

 

 

 

 

 

 

 

Balance at 1 October 2014

728

142

2,615

4,540

204

905

9,134

Additions

-

573

343

1,653

-

99

2,668

On acquisition

-

-

3

5,690

-

23

5,716

Exchange differences

-

-

-

(102)

-

-

(102)

Balance at 31 March 2015 (unaudited)

728

715

2,961

11,781

204

1,027

17,416

 

 

 

 

 

 

 

 

Balance at 1 April 2015

 

 

 

 

 

 

 

Additions

264

10,023

-

-

-

79

10,366

On acquisition

4,638

-

74

(4,160)

-

48

600

Reclassification

-

354

(215)

14

-

(153)

-

Exchange differences

-

-

(39)

133

-

(10)

84

Disposals

-

-

(60)

(211)

-

(1)

(272)

Balance at 30 September 2015 (audited)

5,630

11,092

2,721

7,557

204

990

28,194

 

 

 

 

 

 

 

 

Balance at 1 October 2015

5,630

11,092

2,721

7,557

204

990

28,194

Additions

-

6,375

1,458

3,217

-

142

11,192

On acquisition

-

555

1,986

2,164

-

312

5,017

Reclassification

(4,902)

(340)

(688)

6,299

-

(369)

-

Reclassified as intangible assets

-

-

-

(7)

-

(18)

(25)

Exchange differences

6

25

402

1,173

-

96

1,702

Disposals

-

-

(43)

(132)

-

(127)

(302)

Balance at 31 March 2016 (unaudited)

734

17,707

5,836

20,271

204

1,026

45,778

 

 

 

 

 

 

 

 

Accumulated Depreciation

 

 

 

 

 

 

 

Balance at 1 October 2014

-

-

234

1,151

145

362

1,892

Depreciation charge for the period

-

-

103

477

27

33

640

Exchange differences

-

-

-

(7)

-

-

(7)

Balance at 31 March 2015 (unaudited)

-

-

337

1,621

172

395

2,525

 

 

 

 

 

 

 

 

Balance at 1 April 2015

-

-

337

1,621

172

395

2,525

Depreciation charge for the period

175

-

150

259

6

74

664

Exchange differences

-

-

-

(33)

-

-

(33)

Disposals

-

-

(36)

(67)

-

-

(103)

Balance at 30 September 2015 (audited)

175

-

451

1,780

178

469

3,053

 

 

 

 

 

 

 

 

Balance at 1 October 2015

175

-

451

1,780

178

469

3,053

Depreciation charge for the period

-

-

231

740

13

80

1,064

Reclassification

(175)

-

5

480

1

(311)

-

Exchange differences

-

-

196

361

-

68

625

Disposals

-

-

-

(107)

-

(81)

(188)

Balance at 31 March 2016 (unaudited)

-

-

883

3,254

192

225

4,554

 

 

 

 

 

 

 

 

Net book value

 

 

 

 

 

 

 

At 31 March 2016 (unaudited)

734

17,707

4,953

17,017

12

801

41,224

At 30 September 2015 (audited)

5,455

11,092

2,270

5,777

26

521

25,141

At 31 March 2015 (unaudited)

728

715

2,624

10,160

32

632

14,891

 

 

12.   Intangible assets

 

 

Websites

Goodwill

Patents and Trademarks

Intellectual Property

Customer Lists

Contracts / Licences

Genetics

Total

 

£000

£000

£000

£000

£000

£000

£000

£000

Cost or valuation

 

 

 

 

 

 

 

 

Balance at 1 October 2014

517

2,701

590

1,678

-

5,025

-

10,511

Additions - on acquisition

-

21,136

-

3,024

1,000

5,273

21,846

52,279

Fair value adjustment

-

128

-

-

-

-

-

128

Additions - externally acquired

-

-

83

-

-

-

-

83

Balance at 31 March 2015 (unaudited)

517

23,965

673

4,702

1,000

10,298

21,846

63,001

 

 

 

 

 

 

 

 

 

Balance at 1 April 2015

517

23,965

673

4,702

1,000

10,298

21,846

63,001

Additions - on acquisition

-

6,795

-

50

327

1,950

275

9,397

Fair value adjustment

-

(128)

-

-

-

-

-

(128)

Additions - externally acquired

-

-

36

-

-

2,675

-

2,711

Exchange differences

-

(930)

-

(15)

-

(575)

(1,865)

(3,385)

Balance at 30 September 2015 (audited)

517

29,702

709

4,737

1,327

14,348

20,256

71,596

 

 

 

 

 

 

 

 

 

Balance at 1 October 2015

517

29,702

709

4,737

1,327

14,348

20,256

71,596

Additions - on acquisition

-

102,919

208

117,019

4,789

25,562

-

250,497

Reclassified from property, plant and equipment

-

-

25

-

-

-

-

25

Additions - externally acquired

-

-

9

-

-

-

-

9

Exchange differences

-

5,243

7

3,770

148

1,425

1,740

12,333

Balance at 31 March 2016 (unaudited)

517

137,864

958

125,526

6,264

41,335

21,996

334,460

 

 

 

 

 

 

 

 

 

Accumulated amortisation and impairment

 

 

 

 

 

 

 

 

Balance at 1 October 2014

459

273

388

-

-

1,570

-

2,690

Amortisation charge for the period

47

-

16

102

33

745

158

1,101

Balance at 31 March 2015 (unaudited)

506

273

404

102

33

2,315

158

3,791

 

 

 

 

 

 

 

 

 

Balance at 1 April 2015

506

273

404

102

33

2,315

158

3,791

Amortisation charge for the period

9

-

45

159

100

1,078

227

1,618

Impairment

-

345

-

-

-

-

-

345

Exchange differences

-

-

-

-

-

(25)

(5)

(30)

Balance at 30 September 2015 (audited)

515

618

449

261

133

3,368

380

5,724

 

 

 

 

 

 

 

 

 

Balance at 1 October 2015

515

618

449

261

133

3,368

380

5,724

Amortisation charge for the period

1

-

31

3,136

148

1,407

270

4,993

Exchange differences

-

-

3

(45)

-

75

48

81

Balance at 31 March 2016 (unaudited)

516

618

483

3,352

281

4,850

698

10,798

 

 

 

 

 

 

 

 

 

Net book value

 

 

 

 

 

 

 

 

At 31 March 2016 (unaudited)

1

137,246

475

122,174

5,983

36,485

21,298

323,662

At 30 September 2015 (audited)

2

29,084

260

4,476

1,194

10,980

19,876

65,872

At 31 March 2015 (unaudited)

11

23,692

269

4,600

967

7,983

21,688

59,210

 

Additions to goodwill, intellectual property and contracts are detailed further in note 15.

 

Current estimates of useful economic lives of intangible assets are as follows:

 

Goodwill

Indefinite

Patents

2 - 5 years

Websites

5 years

Trademarks

2 - 5 years

Contracts and licences

3 - 20 years

Customer lists

Up to 26 years

Intellectual property

Up to 20 years

Genetics

10 - 40 years

 

 

13.   Loans and borrowings

 

On 30 December 2015 the Group entered into a committed revolving credit facility of up to $70m, with a term of five years. Interest on drawn amounts is payable at a variable rate based on LIBOR plus a margin, which is dictated by the performance of the Group. As at 31 March 2016 the Group had drawn down $55m against the facility. The facility is secured on certain of the Group's assets.

 

14.   Trading and Investing Activities

 

The Group separates its operations into Trading Activities and Investing Activities in order to report the performance of its business. Trading Activities are those operations which generate earnings in the current period. Investing Activities are those activities which have no associated income stream in the current period, but which are intended to provide the Group with income generating operations in future periods. These measures are used by management for planning and reporting purposes and in discussions with and presentations to investment analysts and are defined below. These measures are not defined in International Financial Reporting Standards and may not be comparable with similarly described measures used by other companies.

 

In arriving at Trading Activities, the following Investing Activities are excluded from reported results:

 

-     exceptional costs relating to the restructuring of the Sustainability Science Division;

-     costs of acquiring new businesses (INVE Aquaculture Holdings B.V. in 2016; Salmobreed AS, Stofnfiskur HF, Improve International, Akvaforsk Genetic Center AS, Akvaforsk Genetic Center Inc, Ascomber Ltd and TomAlgae in 2015);

-     pre-operational expenses for new ventures;

-     expenditure on research and development, where the criteria for capitalising development costs has not been met.

 

A reconciliation of reported earnings to earnings from Trading Activities is shown below.

 

Reconciliation of Reported Earnings to Earnings from Trading Activities - Six months ended 31 March 2016

 

 

 

Investing Activities

 

 

6 months
ended 31
March 2016
(unaudited)

Exceptional Items

Acquisition related costs

Pre-operational expenses for new ventures

R&D expenditure

Trading Activities

 

£000

£000

£000

£000

£000

£000

 

 

 

 

 

 

 

Revenue

47,965

-

-

-

-

47,965

Cost of sales

(27,012)

-

-

-

-

(27,012)

Gross profit

20,953

 

-

-

-

20,953

Operating costs

(30,048)

294

11,761

505

5,999

(11,489)

EBITDA

(9,095)

294

11,761

505

5,999

9,464

Depreciation

(1,064)

-

-

-

84

(980)

Amortisation

(4,993)

-

-

-

123

(4,870)

Operating (loss) / profit

(15,152)

294

11,761

505

6,206

3,614

Finance cost

(1,255)

-

-

-

1

(1,254)

Finance income

3,790

-

(3,731)

(12)

-

47

(Loss) / profit on ordinary activities before taxation

(12,617)

294

8,030

493

6,207

2,407

Tax on (loss) / profit on ordinary activities

1,262

-

-

-

(230)

1,032

(Loss) / profit for the period

(11,355)

294

8,031

493

5,977

3,439

Earnings per share (pence)

(3.09)

0.08

2.19

0.13

1.63

0.94

Weighted average number of shares (thousands)

367,017

367,017

367,017

367,017

367,017

367,017

The £3.7m gain in finance income in acquisition related costs relates to a gain made on a forward contract entered into to fix the exchange rate for the US dollar consideration paid on the INVE acquisition.

 

 

14.   Trading and Investing Activities (continued)

 

Reconciliation of Reported Earnings to Earnings from Trading Activities - Six months ended 31 March 2015

 

 

Investing Activities

 

 

6 months
ended 31
March 2015
(unaudited)

Exceptional Items

Acquisition related costs

Pre-operational expenses for new ventures

R&D expenditure

Trading Activities

 

£000

£000

£000

£000

£000

£000

 

 

 

 

 

 

 

Revenue

19,779

-

-

-

-

19,779

Cost of sales

(12,870)

-

-

-

-

(12,870)

Gross profit

6,909

-

-

-

-

6,909

Operating costs

(9,130)

20

(120)

1,088

2,420

(5,722)

EBITDA

(2,221)

20

(120)

1,088

2,420

1,187

Depreciation

(640)

-

-

-

-

(640)

Amortisation

(1,101)

-

-

-

184

(917)

Operating (loss) / profit

(3,962)

20

(120)

1,088

2,604

(370)

Finance cost

125

-

-

-

-

125

(Loss) / profit on ordinary activities before taxation

(3,837)

20

(120)

1,088

2,604

(245)

Tax on (loss) / profit on ordinary activities

(518)

-

-

-

-

(518)

(Loss) / profit for the period

(4,355)

20

(120)

1,088

2,604

(763)

Earnings per share (pence)

(2.49)

0.01

(0.07)

0.59

1.43

(0.53)

Weighted average number of shares (thousands)

183,131

183,131

183,131

183,131

183,131

183,131

 

Reconciliation of Reported Earnings to Earnings from Trading Activities - 12 months ended 30 September 2015

 

 

Investing Activities

 

 

12 months
ended 30
September 2015
(audited)

Exceptional Items

Acquisition related costs

Pre-operational expenses for new ventures

R&D expenditure

Trading Activities

 

£000

£000

£000

£000

£000

£000

 

 

 

 

 

 

 

Revenue

44,199

-

-

-

-

44,199

Cost of sales

(28,102)

-

-

-

-

(28,102)

Gross profit

16,097

-

-

-

-

16,097

Operating costs

(23,328)

160

1,334

1,565

6,595

(13,674)

EBITDA

(7,231)

160

1,334

1,565

6,595

2,423

Depreciation

(1,304)

-

-

118

73

(1,113)

Amortisation

(3,064)

-

-

-

239

(2,825)

Operating (loss) / profit

(11,599)

160

1,334

1,683

6,907

(1,515)

Finance cost

(34)

-

-

-

-

(34)

Finance income

274

-

-

(2)

(12)

260

Loss on ordinary activities before taxation

(11,359)

160

1,334

1,681

6,895

(1,289)

Tax on loss on ordinary activities

(396)

-

-

(4)

(351)

(751)

(Loss) / profit for the period

(11,755)

160

1,334

1,677

6,544

(2,040)

Earnings per share (pence)

(5.96)

0.08

0.66

0.83

3.26

(1.13)

Weighted average number of shares (thousands)

201,280

201,280

201,280

201,280

201,280

201,280

 

 

 

15.   Business combinations

 

On 30 December 2015, Benchmark Holdings plc completed the acquisition of 100% of INVE Aquaculture Holding B.V. ("INVE"), a leading specialist manufacturer of primary stage technically advanced nutrition and health products for aquaculture, for a total consideration of $342 million (approximately £230.7 million).

 

In view of the size of the acquisition relative to the Group, the transaction was classified as a reverse takeover under the AIM rules.  For accounting purposes, Benchmark Holdings plc has been identified as the acquirer and the transaction has been accounted for using the acquisition method.  This is because Benchmark Holdings plc has obtained control over the operations of INVE as a result of the transaction.

 

Certain intangible assets have been separately identified and provisionally valued as shown in the table below. Related deferred tax has also been provided.  The goodwill arising on the acquisition represents the synergies available from combining the two businesses, and the skills and technical talent of the INVE workforce.

 

Details of the provisional fair values recognised for the consideration paid and assets acquired during the period are shown below:

 

 

 

INVE Aquaculture Holdings B.V.

 

 

 

£000 

Consideration

 

 

 

Cost of investment

 

 

230,667

 

 

 

 

Satisfied by:

 

 

 

Cash

 

 

197,440

Equity

 

 

33,227

Total consideration

 

 

230,667

 

 

 

 

Fair value of assets acquired

 

 

 

Customer list

 

 

4,789

Patents and trademarks

 

 

208

Intellectual property

 

 

117,019

Contracts and Licences

 

 

25,562

Deferred tax on intangibles

 

 

(50,106)

Fixed assets

 

 

5,017

Investments

 

 

350

Inventories

 

 

16,686

Trade and other receivables

 

 

14,914

Cash and cash equivalents

 

 

6,647

Trade and other payables

 

 

(10,104)

Tax and social security

 

 

(2,373)

Loans and borrowings

 

 

(570)

Provisions

 

 

(291)

Total identifiable net assets

 

 

127,748

Goodwill

 

 

102,919

 

INVE contributed £20.6m to group revenue and £7.1 million to trading EBITDA in the six months ended 31 March 2016. If the acquisition had taken place at the start of the period Group revenue and trading EBITDA would have been higher by £14.2 million and £2.3million respectively.

 

In addition, during the period, the Group paid deferred consideration of £383,000 for Akvaforsk Genetics Center AS, which was acquired on 27 July 2015.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR LLFIARVIDFIR

a d v e r t i s e m e n t